LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

Xilio Therapeutics

Xilio Therapeutics is a biopharmaceutical company focused on developing highly-potent, targeted immuno-oncology therapeutics. The company’s proprietary Aklusion™ platform technology allows biologics to be specifically activated in the tumor microenvironment, and with precisely tailored properties, expanding the universe of natural immune-activating proteins that can be safely delivered. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for patients living with cancer. To learn more, please visit
The company is financed by blue chip investors F-Prime Capital Partners and Atlas Venture.  Xilio has licensed key technology from Thomas Jefferson University and City of Hope. The company is located in Cambridge, Massachusetts.

  • Rene Russo Chief Executive Officer
  • Joseph Farmer Chief Operating Officer
  • Tim Clackson President & EVP R&D
  • Ronan O'Hagan SVP Research & Translational Sciences